Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program

Aim Hepatitis C virus (HCV) recombinant form RF1_2k/1b is common in ethnic Georgians. This chimera virus contains genomic fragments of genotype 2 and genotype 1 and is misclassified as genotype 2 by standard genotyping. We aimed to identify RF1_2k/1b strains among genotype 2 patients and assess its...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2018-01, Vol.48 (1), p.36-44
Main Authors: Karchava, Marine, Chkhartishvili, Nikoloz, Sharvadze, Lali, Abutidze, Akaki, Dvali, Natia, Gatserelia, Lana, Dzigua, Lela, Bolokadze, Natalia, Dolmazashvili, Ekaterine, Kotorashvili, Adam, Imnadze, Paata, Gamkrelidze, Amiran, Tsertsvadze, Tengiz
Format: Article
Language:English
Subjects:
Chimeras
Clinical outcomes
DAA treatment
Genotype & phenotype
Genotypes
Genotyping
HCV recombinant strain
Hepatitis
Hepatitis C
Interferon
Ribavirin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Hepatitis C virus (HCV) recombinant form RF1_2k/1b is common in ethnic Georgians. This chimera virus contains genomic fragments of genotype 2 and genotype 1 and is misclassified as genotype 2 by standard genotyping. We aimed to identify RF1_2k/1b strains among genotype 2 patients and assess its impact on treatment outcomes. Methods The study included 148 patients with HCV genotype 2 as determined by 5‐untranslated region/core genotyping assay. RF1_2k/1b was identified by sequencing the non‐structural protein 5B region. Patients were treated within the national hepatitis C elimination program with sofosbuvir/ribavirin (SOF/RBV), interferon (IFN)/SOF/RBV, or ledipasvir (LDV)/SOF/RBV. Results Of 148 patients, 103 (69.5%) had RF1_ 2k/1b. Sustained virologic response (SVR) data was available for 136 patients (RF1_ 2k/1b, n = 103; genotype 2, n = 33). Sustained virologic response was achieved in more genotype 2 patient than in RF1_2k/1b patients (97.0% vs. 76.7%, P = 0.009). Twelve weeks of LDV/SOF/RBV treatment was highly effective (100% SVR) in both genotypes. Among RF1_2k/1b patients, LDV/SOF/RBV for 12 weeks was superior (100% SVR) to SOF/RBV for 12 weeks (56.4%, P 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.12890